European journal of hospital pharmacy : science and practice最新文献

{"title":"Managing refractory cytomegalovirus in an immunosuppressed patient with sarcoidosis: a case report on maribavir therapy.","authors":"Maria Antonia Meroño Saura, María Garcia Coronel, Lorena Rentero-Redondo, Elena Urbieta-Sanz","doi":"10.1136/ejhpharm-2024-004445","DOIUrl":"10.1136/ejhpharm-2024-004445","url":null,"abstract":"<p><p>Cytomegalovirus (CMV) is a common herpesvirus that can cause severe infections in immunocompromised patients. Standard treatments, such as ganciclovir and valganciclovir, are usually effective, but refractory CMV requires alternatives like foscarnet, cidofovir, or immunotherapies. New treatments, such as maribavir, have shown promise for refractory cases. This report discusses a woman in her 50s with sarcoidosis, previously treated with infliximab, leflunomide, and hydroxychloroquine, who developed refractory CMV. Initial treatment with ganciclovir and intravenous immunoglobulin (IVIG) was discontinued due to severe pancytopenia, leading to the initiation of foscarnet. Despite this, CMV viremia persisted, leading to off-label use of maribavir, which reduced the viral load with mild gastrointestinal side effects. The patient also developed haemophagocytic syndrome, complicating her condition.Unfortunately, she succumbed to an opportunistic infection, leaving the complete efficacy of maribavir unconfirmed. This case highlights the potential of novel antiviral agents and underscores the need for further research on refractory CMV management.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"287-289"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Realising potential and addressing risk: a UK survey of adult hepatology pharmacy services.","authors":"Sital Shah, Claire Bullen, Dane Howard, Fatema Jessa, Georgina Tucker, Helen Boothman","doi":"10.1136/ejhpharm-2025-004625","DOIUrl":"10.1136/ejhpharm-2025-004625","url":null,"abstract":"<p><strong>Objective: </strong>The pharmacy workforce in areas such as critical care and renal services has been well described, but little is known about the UK hepatology pharmacy workforce, service provision and capability. Our objective was to understand the current workforce in terms of staffing levels, skill mix, roles and risks.</p><p><strong>Method: </strong>We conducted a multicentre, cross-sectional electronic survey inviting one pharmacy professional response per UK centre providing hepatology pharmacy services. We collated information on workforce, service provision and pharmaceutical care activities provided by pharmacy teams in hepatology specialities.</p><p><strong>Results: </strong>Seventeen centres responded to this survey, which was composed of five (29%) district general hospitals, two (12%) providing both secondary and tertiary level hepatology services, three (18%) secondary care centres and seven (41%) centres providing tertiary level care. There are a greater number of posts in tertiary level care centres irrespective of inpatient beds covered. Consultant pharmacists were only present in tertiary level care centres. A large portion of pharmacy time is spent on indirect pharmaceutical care, which ranged from 10% to 50%. Overall, 75% of respondents felt that their team's workload was safe, though this was only 45% in district general hospitals.</p><p><strong>Conclusion: </strong>Clinical hepatology pharmacy staffing levels vary across the UK. Recognition and benchmarking are key across all levels of care to ensure this workforce remains sustainable given the increasing incidence of liver disease in the UK.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"254-259"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specialisation School of Hospital Pharmacy, Italy: advancing excellence and fostering global unity.","authors":"Andrea Falzon, Cristiana Bruno, Roberto Brunoro, Giaime Maria Corda, Luigi Fortino, Esteban Zavaleta","doi":"10.1136/ejhpharm-2024-004447","DOIUrl":"10.1136/ejhpharm-2024-004447","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"293"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physicochemical stability of a polysorbate-80-containing solvent compounded in the hospital pharmacy and used to reconstitute a biologic for nebulisation.","authors":"Laura Négrier, Marine Roche, Damien Lannoy, Christophe Berneron, Léa Pacqueu, Christophe Carnoy, Antoine Guillon, Benjamin Hamzé, Jean-Claude Sirard, Bertrand Décaudin, Pascal Odou, Cécile Danel","doi":"10.1136/ejhpharm-2024-004441","DOIUrl":"10.1136/ejhpharm-2024-004441","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the long-term physicochemical stability of a solvent (10 mM phosphate buffer pH 6.5 containing sodium chloride (145 mM) and polysorbate 80 (PS80) 0.02%) used to reconstitute a biologic for nebulisation. The solvent was compounded in the hospital pharmacy and stored in amber glass vials at -20°C for 1 year.</p><p><strong>Methods: </strong>Samples were analysed immediately on compounding and then 1, 3, 6, 9 and 12 months after storage at -20°C (immediately after thawing, and also 1 month later keeping the vials at 2-8°C). The assays included a visual examination, measurement of the pH, osmolality, sub-visible particulate contamination, the concentration of PS80, and the concentration of oleic acid and peroxides (both major markers of PS80 degradation). Quantification of PS80 was challenging due to the substance's molecular heterogeneity and the lack of a good chromophore. The strategy adopted consisted of hydrolysis in a strong base and then liquid-liquid extraction of the oleic acid (PS80's hydrolysis product). The oleic acid content was determined using reversed phase high performance liquid chromatography with ultraviolet detection. The peroxide content was determined spectrophotometrically using a ferrous oxidation with xylenol orange assay.</p><p><strong>Results: </strong>Over 12 months, there was no significant change in the samples' visual appearance, pH and osmolality. The PS80 concentration remained above 90% of the initial value. The subvisible particle counts remained far below the European Pharmacopoeia thresholds. The oleic acid content of the non-hydrolysed samples remained constant, and no peroxide was detected.</p><p><strong>Conclusions: </strong>A PS80-containing solvent is stable for 1 year when stored at -20°C (±5°C) in amber glass vials. Moreover, the solvent is stable for up to 1 month after thawing if stored at 2-8°C.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"272-277"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective study of plasma anti-Xa levels in renally impaired patients receiving reduced or non-reduced therapeutic doses of dalteparin.","authors":"Katia Christina Pires, Lieke Mitrov-Winkelmolen, Hoang Lan Le, Rogier A M Quax, Rikje Ruiter, Marieke Wabbijn, T Martijn Kuijper, Tessa Bosch","doi":"10.1136/ejhpharm-2024-004452","DOIUrl":"10.1136/ejhpharm-2024-004452","url":null,"abstract":"<p><strong>Background: </strong>In renally impaired patients, guidelines recommend a 25-50% dalteparin dose reduction with anti-Xa monitoring to reduce bleeding risk. However, pharmacokinetic considerations and results from previous studies dispute the need for dose reduction. Therefore, in our hospitals an alternative dose reduction to 75% or a 100% is used. This study aimed to assess anti-Xa levels to confirm or refute the need for dose reduction and to investigate the association between dose, anti-Xa levels and bleeding events.</p><p><strong>Methods: </strong>This multicentre retrospective observational study included patients aged ≥18 years during a 3-year period with an estimated glomerular filtration rate of <60 mL/min/1.73 m² or on renal replacement therapy, receiving ≥7500 IU dalteparin daily. Only correctly sampled plasma anti-Xa levels were included and stratified into intensive care unit (ICU) and non-ICU patients. Stratum-adjusted odds ratios were determined to compare the likelihood of achieving adequate anti-Xa levels between a 75% and 100% dose. Bleeding events were classified into minor and major events.</p><p><strong>Results: </strong>A total of 167 anti-Xa levels were included, with 148 anti-Xa levels belonging to patients receiving a 75% or 100% dose. Anti-Xa levels were highly scattered: 55% below and 6% above the anti-Xa ranges. In all patients the probability that anti-Xa levels fell within the range was higher for patients receiving a 100% dose than for those receiving a 75% dose (OR 2.66, 95% CI 1.24 to 5.70, p=0.012). Eight bleeding events occurred, including one minor event in a patient with an anti-Xa level above range and five events in patients on renal replacement therapy with anti-Xa levels within or below range.</p><p><strong>Conclusions: </strong>In renally impaired patients a 100% dalteparin dose increases the likelihood of achieving adequate anti-Xa levels compared with a 75% dose, without leading to over-exposure. The occurrence of bleeding events did not differ between the 75% and 100% dose groups and appeared unrelated to anti-Xa levels. Pre-emptive dose reduction of dalteparin in renally impaired patients is likely to be unnecessary.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"224-231"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A collaborative telepharmacy model for dispensing and informed delivery from hospital to community pharmacies.","authors":"Esther Vicente-Escrig, Antonio Solana-Altabella, Maria José Company-Albir, Mayte Gil-Candel, Raul Ferrando-Piqueres, Maria Dolores Belles-Medall","doi":"10.1136/ejhpharm-2025-004524","DOIUrl":"10.1136/ejhpharm-2025-004524","url":null,"abstract":"<p><strong>Background: </strong>This study examines the implementation of a collaborative telepharmacy programme in an outpatient pharmaceutical care unit (OPCU) at a tertiary hospital. The programme coordinates between the hospital pharmacy, community pharmacies, a pharmaceutical distributor, and the regional official college of pharmacists to optimise medication dispensing and delivery to outpatients.</p><p><strong>Methods: </strong>The programme addressed challenges in operations, logistics, technology, legality, training and information. A protocol was developed defining the collaborative dispensing circuit, including criteria for patient selection and prioritisation.</p><p><strong>Results: </strong>Over 39 months, 13 310 shipments were made to 1039 patients, averaging 17 daily. Each patient received about 13 deliveries. A total of 14 283 medications from 258 specialties were dispensed. The programme saved 512 534 km and 542 164 min (356 days) in travel. Each patient saved approximately 493 km and 522 min, reducing CO2 emissions by 58-116 kg per patient, or 72-145 tonnes overall. A survey of 130 patients revealed a 93% preference for this model over home or healthcare facility delivery.</p><p><strong>Discussion: </strong>The implementation of telepharmacy programmes for dispensing hospital medication to community pharmacies marks a significant advancement in patient care. Initially rare, telepharmacy is now widespread, overcoming previous barriers. Programmes show similar effectiveness to home delivery, improving workflow and safety. Future improvements may include remote monitoring tools and video calls. Despite some limitations, such as economic analysis and tracking, telepharmacy has proven beneficial for patients, offering cost savings and enhanced confidentiality.</p><p><strong>Conclusion: </strong>The collaborative telepharmacy circuit was efficiently and safely implemented, offering an innovative approach that meets the needs and expectations of patients in the OPCU.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"232-238"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compatibility and physicochemical stability of ceftriaxone for injection admixed with pantoprazole sodium and ondansetron hydrochloride in different infusion solutions.","authors":"Ashish Dobariya, Rashmin Patel, Mrunali Patel","doi":"10.1136/ejhpharm-2025-004511","DOIUrl":"10.1136/ejhpharm-2025-004511","url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to analyse the physicochemical stability and compatibility of ceftriaxone sodium (CEF) (2mg/mL) with pantoprazole sodium (PAN) (0.08mg/mL) and ondansetron hydrochloride (OND) (0.008mg/mL) in different infusion solutions, specifically 0.9% sodium chloride injection (NS) and 5% dextrose injection (5D) under varied temperature conditions, including 2°C to 8°C, 25°C, and 37°C at different time intervals.</p><p><strong>Method: </strong>This study involved determining the content of CEF, PAN and OND in infusion solutions, NS and 5D under varied temperature conditions, including 2°C to 8°C, 25°C, and 37°C at different time intervals using high performance liquid chromatography, visual description of solution mixture, pH measurement, osmolality, particulate matter (both visible and subvisible), as well as assessing the colour and clarity of the solution (measured by absorbance at 420 nm and % transmittance at 650 nm).</p><p><strong>Results: </strong>No significant changes were observed in pH, osmolality, particulate matter, colour and clarity of admixture in NS up to 48 hours at all conditions. CEF, PAN and OND retained more than 90% of their initial concentration at 2°C to 8°C for 48 hours, 25°C for 8 hours, and 37°C for 8 hours. Also, no significant changes were observed in pH and osmolality of admixture in 5D up to 48 hours at all conditions. CEF, PAN and OND retained more than 90% of their initial concentration at 2°C to 8°C for 4 hours, 25°C for less than 2 hours, and 37°C for less than 2 hours.</p><p><strong>Conclusion: </strong>This study concludes that the physicochemical stability of a ternary admixture containing CEF, PAN and OND is diluent and temperature dependent. NS ensures acceptable stability, whereas 5D causes rapid degradation. For safety and efficacy, NS is recommended, with refrigerated storage preferred. Based on physicochemical stability data, the use of this parenteral admixture with 5D is not recommended.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"278-283"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing depression management in older cancer patients: the pharmacist's role.","authors":"Rojita Jadhari, Nabin Pathak, Shreya Dhungana, Ajaya Acharya, Sunil Shrestha","doi":"10.1136/ejhpharm-2025-004682","DOIUrl":"10.1136/ejhpharm-2025-004682","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"197-198"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution rate of prescribing errors after advice from a specialised hospital pharmacist or a substitute hospital pharmacist: a retrospective cross-sectional study.","authors":"Sarah Wilkes, Laura Kalfsvel, Floor van Rosse, Jorie Versmissen, Hugo van der Kuy, Rianne Zaal","doi":"10.1136/ejhpharm-2024-004392","DOIUrl":"10.1136/ejhpharm-2024-004392","url":null,"abstract":"<p><strong>Objectives: </strong>Specialised hospital pharmacists, integrated in medical teams on the ward, can improve medication safety. When a specialised hospital pharmacist is temporarily not available, the pharmaceutical care will be conducted by a substitute hospital pharmacist with less specific knowledge about that patient population. Our objective was to compare the resolution rate of prescribing errors between specialised hospital pharmacists and their substitutes. Furthermore, we investigated whether other characteristics of the pharmacists, the prescriber, patient, drug or intervention itself were associated with the resolution rate.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was conducted to assess the resolution of prescribing errors, based on the analysis of electronic prescriptions. A prescribing error was defined as an alert that required intervention of the pharmacist to prevent harm or to optimise therapy. To identify prescribing errors, a medical doctor and hospital pharmacist analysed all alerts that were retained to be checked by a pharmacist. Resolution of a prescribing error was defined as resolution of the error within 24 hours after detection.</p><p><strong>Results: </strong>In total, 145 574 medication prescriptions were analysed and 448 prescribing errors were detected. Of these prescribing errors, 94.0% were resolved within 24 hours. No differences were found between the resolution rate of prescribing errors after advice from a specialised hospital pharmacists and their substitutes (94.4% vs 91.9%, p=0145 (χ² test)). Administrative prescribing errors, prescribing errors for patients aged >80 years and prescribing errors handled during weekends showed a relatively low-resolution rate. No other characteristics of the pharmacist, prescriber, patient, the drug involved or the intervention itself were associated with the resolution of the prescribing error.</p><p><strong>Conclusions: </strong>In the temporarily absence of a specialised hospital pharmacist, the resolution rate of prescribing errors remains high when advice about prescribing errors is provided by a substitute hospital pharmacist.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"206-212"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Algorithm-managed dosing and pharmacist-managed dosing of erythropoietin stimulating agents in renal anaemia: a systematic review.","authors":"Francisca Johanna van den Oever, Marijke J E Dekker, Erwin C Vasbinder, Teun van Gelder, Patricia M L A Van den Bemt","doi":"10.1136/ejhpharm-2024-004366","DOIUrl":"10.1136/ejhpharm-2024-004366","url":null,"abstract":"<p><strong>Objectives: </strong>The goal of this systematic review was to identify and summarise algorithm-managed and pharmacist-managed dosing of erythropoietin stimulating agents (ESA) in patients with renal anaemia and to determine the effects on available outcome parameters.</p><p><strong>Methods: </strong>We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines for systematic reviews. Studies investigating algorithm-managed and pharmacist-managed dosing of ESA in adult patients with renal anaemia were evaluated for inclusion. No restrictions were set on outcome parameters. Observational and interventional studies available as full-text articles with a control group and follow-up ≥6 months were eligible for inclusion. Relevant databases were searched from their inception through August 2024. Two independent reviewers evaluated all studies. The risk of bias was assessed by the ROBINS-I and RoB1 tools. The protocol of this study was registered in PROSPERO (CRD42021243678).</p><p><strong>Results: </strong>After screening 140 articles, 17 articles and 4313 patients could be included. Available evidence was of low to moderate quality with a high risk of bias. Data were summarised and tabulated. Meta-analysis was not possible due to the substantial heterogeneity in participants, study design, interventions, comparisons, and outcome parameters. However, standardised metrics could be identified and calculated for haemoglobin and ESA dose. The percentage in target range for haemoglobin varied between 3.5% lower (95% CI -18.67% to +11.67%) to 32.0% higher (95% CI 14.07% to 49.93%) in the pharmacist-managed group versus the control group (n=1401). The range in reduction in ESA dose was 5.45% (95% CI -7.97% to +18.87%) to 49.97% (95% CI 20.32% to 79.61%) in the pharmacist-managed group versus the control group (n=2115).</p><p><strong>Conclusion: </strong>Low-quality data with high risk of bias suggest that pharmacist-managed renal anaemia may improve the percentage of haemoglobin within target range and reduce the ESA dose. However, meta-analysis was impossible due to substantial heterogeneity. Therefore, no definite conclusions could be drawn on the effectiveness of pharmacist-managed dosing of ESA in renal anaemia.</p><p><strong>Prospero registration number: </strong>CRD42021243678.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"199-205"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}